Monoiodinated, Met35-oxidized muscarinic toxin 7 (MT7ox) was synthesized, and its affinity constants for free or N-methyl scopolamine (NMS)-occupied hM 1 receptor were measured directly by equilibrium and kinetic binding experiments. Identical values were obtained with the two types of assay methods, 14 pM and 0.9 nM in free or NMS-liganded receptor states, respectively, highlighting a strong negative cooperativity between this allosteric toxin and NMS. Identical results were obtained with indirect binding experiments with [3 H]NMS using the ternary complex model, clearly demonstrating the reciprocal nature of this cooperativity. Furthermore, the effects of various orthosteric and allosteric agents on the dissociation kinetic of 125 I-MT7ox were measured and show that, except for the MT1 toxin, all of the ligands studied [NMS, atropine, gallamine, brucine, tacrine, staurosporine, and (9S,10S,12R)-2,3,9,10,11-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3Ј,2Ј,1Ј-kl]pyrrolo [3,4-i][1,6]benzodiazocine-10-carboxylic acid hexyl ester (KT5720)] interact allosterically with muscarinic toxin 7. Equilibrium binding experiments with 125 IMT7ox and [3 H]NMS were conducted to reveal the effects of these ligands on the free receptor, and affinity constants (pK x values) were calculated using the allosteric ternary complex model. Our results suggest that MT7 toxin interacts with hM 1 receptor at a specific allosteric site, which may partially overlap those identified previously for "classic" or "atypical" allosteric agents and highlight the potential of this new allosteric tracer in studying allosterism at muscarinic receptors.An increasing body of evidence now shows that many Gprotein-coupled receptors are susceptible to allosteric modulation (Christopoulos and Kenakin, 2002), and this phenomenon is particularly well documented for the five muscarinic acetylcholine receptor subtypes (Tucek and Proska, 1995;Birdsall et al., 1997;Ellis, 1997;Lazareno et al., 2004;Birdsall and Lazareno, 2005). These receptors are characterized by at least two distinct binding sites. Agonists and competitive antagonists bind to the orthosteric site, located inside the transmembrane domain, whereas allosteric agents induce a positive or a negative alteration of the orthosteric ligand affinity by interacting with an allosteric site, located more extracellularly (Stockton et al., 1983;Ellis et al., 1993;Ellis, 1997;Trankle and Mohr, 1997;Christopoulos et al., 1998;Christopoulos and Kenakin, 2002). Furthermore, recent publications report the presence of at least two distinct allosteric sites on muscarinic receptors selective for distinct classes of allosteric agents, suggesting that it is possible for three small ligands to bind simultaneously to a muscarinic receptor (Birdsall et al., 2001;Lazareno et al., 2002). For instance, staurosporine and other indolocarbazole compounds have been shown to interact at a second allosteric site on hM 1 receptor, associated with a positive cooperativity with ACh (Lazareno et al., 20...